New York University's breach of contract lawsuit against Pfizer over hundreds of millions of dollars in cancer drug royalties must go forward, a divided Manhattan appeals court has ruled.
May 04, 2017 at 04:03 PM
1 minute read
New York University’s breach of contract lawsuit against Pfizer over hundreds of millions of dollars in cancer drug royalties must go forward, a divided Manhattan appeals court has ruled.
A 3-2 Appellate Division, First Department, panel reversed the dismissal of NYU’s 25-page complaint, which focuses on the university’s disputed role in the development of Xalkori, a drug used to treat lung cancer.
Presented by BigVoodoo
The New York Law Journal honors attorneys and judges who have made a remarkable difference in the legal profession in New York.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
